186 Development of KSQ-001, an engineered TIL (eTIL) therapy for solid tumors through CRISPR/Cas9-mediated editing of SOCS1 von Wong, Karrie, Lin, Sharon, Wrocklage, Christopher, Sofjan, Katri, Williams, Leila, Brady, Mallory, Colletti, Nicholas, Tubo, Noah, Gannon, Hugh, LaMothe, Robert, Xu, Tianlei, VandenBerg, Tracy, Shenker, Sol, Dugopolski, Caroline, Stegmeier, Frank, Cadzow, Louise, Schlabach, Michael, Benson, Micah

Volltext

Rational design of a SOCS1-edited tumor-infiltrating lymphocyte therapy using CRISPR/Cas9 screens von Schlabach, Michael R, Lin, Sharon, Collester, Zachary R, Wrocklage, Christopher, Shenker, Sol, Calnan, Conor, Xu, Tianlei, Gannon, Hugh S, Williams, Leila J, Thompson, Frank, Dunbar, Paul R, LaMothe, Robert A, Garrett, Tracy E, Colletti, Nicholas, Hohmann, Anja F, Tubo, Noah J, Bullock, Caroline P, Le Mercier, Isabelle, Sofjan, Katri, Merkin, Jason J, Keegan, Sean, Kryukov, Gregory V, Dugopolski, Caroline, Stegmeier, Frank, Wong, Karrie, Sharp, Fiona A, Cadzow, Louise, Benson, Micah J

Volltext

Rational design of a SOCSI-edited tumor-infiltrating lymphocyte therapy using CRISPR/Cas9 screens von Schlabach, Michael R, Lin, Sharon, Collester, Zachary R, Wrocklage, Christopher, Shenker, Sol, Calnan, Conor, Xu, Tianlei, Gannon, Hugh S, Williams, Leila J, Thompson, Frank, Dunbar, Paul R, LaMothe, Robert A, Garrett, Tracy E, Colletti, Nicholas, Hohmann, Anja F, Tubo, Noah J, Bullock, Caroline P, Mercier, Isabelle Le, Sofjan, Katri, Merkin, Jason J, Keegan, Sean, Kryukov, Gregory V, Dugopolski, Caroline, Stegmeier, Frank, Wong, Karrie, Sharp, Fiona A, Cadzow, Louise, Benson, Micah J

Volltext

Abstract 1337: Functional genomic characterization of the USP1 inhibitor KSQ-4279 reveals a distinct mechanism of action and resistance profile relative to other DDR targeting drug... von Shenker, Sol, Gannon, Hugh, Carlson, Alyssa, Grasberger, Paula, Sullivan, Pamela, Middleton, Chris, Dodson, Anne, Bullock, Caroline, McGuire, Michael, Tobin, Erica, Sinkevicius, Kerstin, Schlabach, Mike, Stegmeier, Frank, Cadzow, Louise, Wylie, Andrew

Volltext

Reverse Translating Molecular Determinants of Anti-Programmed Death 1 Immunotherapy Response in Mouse Syngeneic Tumor Models von Georgiev, Peter, Muise, Eric S, Linn, Douglas E, Hinton, Marlene C, Wang, Yun, Cai, Mingmei, Cadzow, Louise, Wilson, Douglas C, Sukumar, Selvakumar, Caniga, Michael, Chen, Lan, Xiao, Hui, Yearley, Jennifer H, Sriram, Venkataraman, Nebozhyn, Michael, Sathe, Manjiri, Blumenschein, Wendy M, Kerr, Kimberly S, Hirsch, Heather A, Javaid, Sarah, Olow, Aleksandra K, Moy, Lily Y, Chiang, Derek Y, Loboda, Andrey, Cristescu, Razvan, Sadekova, Svetlana, Long, Brian J, McClanahan, Terrill K, Pinheiro, Elaine M

Volltext

Abstract B25: Development of a nanoparticle containing the PI3K/mTOR dual Inhibitor, gedatolisib, for cancer therapy von Zhang, Lianglin, Troche, Gabriel, Visswanathan, Ravi, Huang, Wenhu, Song, Young-Ho, Spilker, Mary E., Wang, Zhenxiong, Wang, Hui, Giddabasappa, Anand, Cadzow, Louise, Low, Susan, Troiano, Greg, Lafontaine, Jennifer, Fantin, Valeria, Abraham, Robert T., Bagrodia, Shubha

Volltext

Abstract 1581: KSQ-4279, a first-in-class USP1 inhibitor shows strong combination activity with multiple PARP inhibitors in BRCA mutant cancers von Tobin, Erica, Sullivan, Pamela, Murray, Morgan, Gannon, Hugh, Dodson, Anne, Shenker, Sol, Stegmeier, Frank, Wylie, Andrew, Cadzow, Louise

Volltext

Abstract 2175: KSQ-001: A CRISPR/Cas9-engineered tumor infiltrating lymphocyte (eTILTM) therapy for solid tumors von Schlabach, Mike, Colletti, Nick, Hohmann, Anja, Wrocklage, Christopher, Gannon, Hugh, Falla, Alejandra, Tubo, Noah, LaMothe, Robert A., Bullock, Caroline, Mitchell, Pete T., Hafeez, Nafeeza, Sathithloetsakun, Suphinya, Grasberger, Paula E., Le Mercier, Isabelle, Garrett, Tracy E., Keegan, Sean, Shenker, Sol, Franco, Charlotte, Stegmeier, Frank, Kryukov, Gregory V., Cadzow, Louise, Benson, Micah

Volltext

Pan-cancer Analysis of Homologous Recombination Deficiency in Cell Lines von Dodson, Anne E, Shenker, Sol, Sullivan, Pamela, Nayak, Sumeet U, Middleton, Chris, McGuire, Michael, Chipumuro, Edmond, Mishina, Yuji, Tobin, Erica R, Cadzow, Louise, Wylie, Andrew A, Sangurdekar, Dipen

Volltext

Abstract C101: Comprehensive identification of novel therapeutic targets for treatment of PD-1 resistant solid tumors via a genome-scale CRISPR/Cas9 in vivo T-cell screen von Mercier, Isabelle Le, Merkin, Jason J., Keegan, Sean, Calnan, Conor, Hohmann, Anja F., Colletti, Nick, Fagerberg, Eric, Shenker, Sol, Bullock, Caroline, Wrocklage, Chris, Tubo, Noah, Xu, Tianlei, Noyes, Matt, Rahal, Rami, Arlauckas, Sean, Morales, Aria Pearlman, Stegmeier, Frank, Cadzow, Louise, Schlabach, Mike, Kryukov, Gregory, Benson, Micah J.

Volltext

Abstract C184: BIND-510 improves the pharmacokinetics, tolerability, tumor accumulation and tumor growth inhibition in preclinical models of cancer compared to vincristine sulfate von Cadzow, Louise, Arnold, Kristen, Thrasher, Daniel, Nolan, James, Horhota, Allen, Lewis-Clark, Eric, Wright, James, Low, Susan

Volltext

Abstract 2771: KSQ-4279 mediated USP1 inhibition induces replication associated DNA gaps that contribute to cell death von Nayak, Sumeet, Sullivan, Pamela, Mishina, Yuji, Dodson, Anne, Kao, Pei-Lun, Gannon, Hugh, Middleton, Chris, Shenker, Sol, Murray, Morgan, Schlabach, Michael, Stegmeier, Frank, Tobin, Erica, Cadzow, Louise, Wylie, Andrew

Volltext

Abstract C197: Accurins improve the pharmacokinetics, pharmacodynamics, tolerability and anti-tumor activity of the AKT inhibitor MK-2206 von Cadzow, Louise, Lam, Michael H., Song, Young Ho, Figueiredo, Maria, Wang, Hong, De Witt, David, Pucci, Vincenzo, Mo, Jan-Rung, Lewis-Clark, Eric, Ferguson, Heidi, Gindy, Marian, Low, Susan, Zale, Steve, Hrkach, Jeff, McGregor, Caroline, Long, Brian J.

Volltext

Abstract ND01: KSQ-4279: A first-in-class USP1 inhibitor for the treatment of cancers with homologous recombination deficiencies von Cadzow, Louise, Tobin, Erica, Sullivan, Pamela, Shenker, Sol, Nayak, Sumeet, Ali, Janid, Gannon, Hugh, Dodson, Anne, Grasberger, Paula, Carlson, Alyssa, McGuire, Michael, Brenneman, Jehrod, Liu, Hanlan, Olaharski, Andrew, Sinkevicius, Kerstin, Hixon, Jeff, Krall, Elsa, Schlabach, Mike, Goulet, Matt, Wilt, Jeremy, Harris, Patricia, Stegmeier, Frank, Wylie, Andrew

Volltext

Abstract 699: Optimized dosing strategies resulting in prolonged pathway inhibition enhance dinaciclib anti-tumor activity in preclinical xenograft models von Schuller, Alwin, Booher, Robert, Cadzow, Louise, Angagaw, Minilik, Harmonay, Lauren, Qu, Xianlu, Miselis, Nathan, Pucci, Vincenzo, Ayers, Mark, Graef, Thorsten, Im, Ellie, Blanchard, Rebecca, Long, Brian, Zawel, Leigh, strack, peter

Volltext

THERAPEUTIC COMBINATIONS COMPRISING UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS AND PARP1-SELECTIVE INHIBITORS von STEGMEIER, Frank, WYLIE, Andrew Alistair, CADZOW, Anne Louise

Volltext bestellen

THERAPEUTIC COMBINATIONS COMPRISING UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS AND PARP1-SELECTIVE INHIBITORS von STEGMEIER, Frank, WYLIE, Andrew Alistair, CADZOW, Anne Louise

Volltext bestellen

THERAPEUTIC COMBINATIONS COMPRISING UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS AND POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS von SULLIVAN, Pamela Jean, SHENKER, Solomon Martin, LIU, Hanlan, STEGMEIER, Frank, SINKEVICIUS, Kerstin Wolf, WYLIE, Andrew Alistair, CADZOW, Anne Louise

Volltext bestellen

THERAPEUTIC COMBINATIONS COMPRISING UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS AND POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS von SULLIVAN, Pamela Jean, SHENKER, Solomon Martin, LIU, Hanlan, STEGMEIER, Frank, SINKEVICIUS, Kerstin Wolf, WYLIE, Andrew Alistair, CADZOW, Anne Louise

Volltext bestellen

COMBINATION GENE TARGETS FOR IMPROVED IMMUNOTHERAPY von FLEUR LE MERCIER, Isabelle, KRYUKOV, Gregory, SCHLABACH, Michael, STEGMEIER, Frank, BENSON, Micah, CADZOW, Anne Louise

Volltext bestellen